GlassScriptPhysician profile
Maggie Ellen Pohlmeier
NPI 1275150757
$1,509.35
in general payments reported to CMS, 2019-2025
12 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.00 · 2023: $239 · 2024: $722 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.88 | 2023-2025 | |
| Alcon Vision LLC | $326.95 | 2023-2025 | Argos, Clareon, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $193.18 | 2020-2025 | Cequa |
| Thea Pharma INC. | $128.36 | 2023-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $119.71 | 2024-2025 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $112.60 | 2024-2025 | Xdemvy |
| Coopervision INC. | $63.23 | 2024 | Misight Contact Lens |
| Oyster Point Pharma, INC. | $51.05 | 2023-2024 | Tyrvaya |
| Sight Sciences, INC. | $38.11 | 2024 | Omni Surgical System |
| Carl Zeiss Meditec USA, INC. | $24.83 | 2024 | Clarus |
| Novartis Pharmaceuticals Corporation | $23.34 | 2023 | |
| Genmab U.S., INC. | $16.11 | 2025 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Pohlmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.